SurvivorNet on MSN
New approval means more bladder cancer patients can access powerful immunotherapy combination: What to know about Keytruda + Padcev
A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...
Therapeutic progress has accelerated, with multiple recent approvals improving outcomes across early-stage, muscle-invasive, and metastatic urothelial carcinoma. FGFR3 and HER2 protein expression by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results